Literature DB >> 11278376

A full biological response to autoantibodies in Graves' disease requires a disulfide-bonded loop in the thyrotropin receptor N terminus homologous to a laminin epidermal growth factor-like domain.

C R Chen1, K Tanaka, G D Chazenbalk, S M McLachlan, B Rapoport.   

Abstract

We observed amino acid homology between the cysteine-rich N terminus of the thyrotropin receptor (TSHR) ectodomain and epidermal growth factor-like repeats in the laminin gamma1 chain. Thyroid-stimulating autoantibodies (TSAb), the cause of Graves' disease, interact with this region of the TSHR in a manner critically dependent on antigen conformation. We studied the role of the cluster of four cysteine (Cys) residues in this region of the TSHR on the functional response to TSAb in Graves' patients' sera. As a benchmark we also studied TSH binding and action. Removal in various permutations of the four cysteines at TSHR positions 24, 29, 31, and 41 (signal peptide residues are 1-21) revealed Cys(41) to be the key residue for receptor expression. Forced pairing of Cys(41) with any one of the three upstream Cys residues was necessary for trafficking to the cell surface of a TSHR with high affinity TSH binding similar to the wild-type receptor. However, for a full biological response to TSAb, forced pairing of Cys(41) with Cys(29) or with Cys(31), but not with Cys(24), retained functional activity comparable with the wild-type TSHR. These data suggest that an N-terminal disulfide-bonded loop between Cys(41) and Cys(29) or its close neighbor Cys(31) comprises, in part, the highly conformational epitope for TSAb at the critical N terminus of the TSHR. Amino acid homology, as well as cysteine pairing similar to the laminin gamma1 chain epidermal growth factor-like repeat 11, suggests conformational similarity between the two molecules and raises the possibility of molecular mimicry in the pathogenesis of Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278376     DOI: 10.1074/jbc.M008001200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Insight into thyroid-stimulating autoantibody interaction with the thyrotropin receptor N-terminus based on mutagenesis and re-evaluation of ambiguity in this region of the receptor crystal structure.

Authors:  Sepehr Hamidi; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2011-08-11       Impact factor: 6.568

2.  Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.

Authors:  Anne P Beigneux; Kazuya Miyashita; Michael Ploug; Dirk J Blom; Masumi Ai; MacRae F Linton; Weerapan Khovidhunkit; Robert Dufour; Abhimanyu Garg; Maureen A McMahon; Clive R Pullinger; Norma P Sandoval; Xuchen Hu; Christopher M Allan; Mikael Larsson; Tetsuo Machida; Masami Murakami; Karen Reue; Peter Tontonoz; Ira J Goldberg; Philippe Moulin; Sybil Charrière; Loren G Fong; Katsuyuki Nakajima; Stephen G Young
Journal:  N Engl J Med       Date:  2017-04-05       Impact factor: 91.245

3.  Small-molecule thyrotropin receptor agonist activates naturally occurring thyrotropin-insensitive mutants and reveals their distinct cyclic adenosine monophosphate signal persistence.

Authors:  Michael D Allen; Susanne Neumann; Marvin C Gershengorn
Journal:  Thyroid       Date:  2011-07-11       Impact factor: 6.568

Review 4.  Chylomicronemia from GPIHBP1 autoantibodies.

Authors:  Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2020-09-18       Impact factor: 5.922

Review 5.  Molecular mimicry and autoimmune thyroid disease.

Authors:  Salvatore Benvenga; Fabrizio Guarneri
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

6.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 7.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

8.  Evidence that factors other than particular thyrotropin receptor T cell epitopes contribute to the development of hyperthyroidism in murine Graves' disease.

Authors:  P N Pichurin; Chun-Rong Chen; Y Nagayama; O Pichurina; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

9.  The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor.

Authors:  Sandra Mueller; Gunnar Kleinau; Mariusz W Szkudlinski; Holger Jaeschke; Gerd Krause; Ralf Paschke
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

10.  Insight into antibody responses induced by plasmid or adenoviral vectors encoding thyroid peroxidase, a major thyroid autoantigen.

Authors:  J Guo; P Pichurin; Y Nagayama; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.